In May 2016, Taylor Weyeneth was an undergraduate at St. John’s University in New York, a legal studies student and fraternity member who organized a golf tournament and other events to raise money for veterans and their families.
Less than a year later, at 23, Weyeneth, was a political appointee and rising star at the Office of National Drug Control Policy, the White House office responsible for coordinating the federal government’s multibillion dollar anti-drug initiatives and supporting President Trump’s efforts to curb the opioid epidemic. Weyeneth would soon become deputy chief of staff.
His brief biography offers few clues that he would so quickly assume a leading role in the drug policy office, a job recently occupied by a lawyer and a veteran government official. Weyeneth’s only professional experience after college and before becoming an appointee was working on Trump’s presidential campaign.
Weyeneth’s ascent from a low-level post to deputy chief of staff is the result, in large part, of staff turnover and vacancies. The story of his appointment and remarkable rise provides insight into the Trump administration’s political appointments and the troubled state of the drug policy office.
Trump has pledged to marshal federal government talent and resources to address the opioid crisis, but nearly a year after his inauguration, the drug policy office, known as ONDCP, lacks a permanent director. At least seven of his administration’s appointees have departed, office spokesman William Eason said. Among them was the general counsel and acting chief of staff, some of whose duties were assumed by Weyeneth, according to a memo obtained by The Washington Post.
But the kid is a Republican and did work for a little while for a company that got busted for steroid importation, so you can see how Trump would consider him qualified.